Novartis earnings rose in the third quarter of 2026, with revenue increasing 4% from a year earlier to $14.52 billion. The Swiss drugmaker raised its full-year profit outlook, even as a $1.9 billion impairment charge tied to a failed experimental drug weighed on net profit.
Novartis earnings and the impairment charge
Core operating profit rose 11% year over year to $6.04 billion in the quarter, Novartis reported on October 27. Strong sales of key drugs and improved profit margins supported the results.
The company also recorded an impairment charge related to del-desiran, an experimental drug that failed. The charge significantly affected net profit, although a net profit figure was not provided.
Full-year profit outlook improves
Novartis revised its full-year profit guidance to flat or modest growth, from a previous forecast of a decline. The outlook is a forecast for 2026, not a completed full-year result.
The company sells prescription medicines globally, focusing on areas including oncology, cardiovascular disease and immunology. The United States is its largest market.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…